What is the share price of Norris Medicines Ltd (NORRIS) today?
The share price of NORRIS as on 18th September 2026 is ₹18.48. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Norris Medicines Ltd (NORRIS) share?
The past returns of Norris Medicines Ltd (NORRIS) share are- Past 1 week: 32.00%
- Past 1 month: 17.48%
- Past 3 months: 35.11%
- Past 6 months: 30.47%
- Past 1 year: 10.55%
- Past 3 years: 61.42%
- Past 5 years: 98.69%
What are the peers or stocks similar to Norris Medicines Ltd (NORRIS)?
The peers or stocks similar to Norris Medicines Ltd (NORRIS) include:What is the market cap of Norris Medicines Ltd (NORRIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Norris Medicines Ltd (NORRIS) is ₹182.41 Cr as of 18th September 2026.What is the 52 week high and low of Norris Medicines Ltd (NORRIS) share?
The 52-week high of Norris Medicines Ltd (NORRIS) is ₹19.63 and the 52-week low is ₹12.What is the PE and PB ratio of Norris Medicines Ltd (NORRIS) stock?
The P/E (price-to-earnings) ratio of Norris Medicines Ltd (NORRIS) is -675.60. The P/B (price-to-book) ratio is -12.05.Which sector does Norris Medicines Ltd (NORRIS) belong to?
Norris Medicines Ltd (NORRIS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Norris Medicines Ltd (NORRIS) shares?
You can directly buy Norris Medicines Ltd (NORRIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Norris Medicines Ltd
NORRIS Share Price
BSE₹18.485.00% (+0.88)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NORRIS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
NORRIS Performance & Key Metrics
NORRIS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -506.70 | -12.05 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
NORRIS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NORRIS Company Profile
Norris Medicines is engaged in business of pharmaceuticals.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
NORRIS Forecast
NORRIS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NORRIS
NORRIS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NORRIS Income Statement
NORRIS Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.52 | 0.74 | 1.27 | 1.11 | 2.77 | 1.48 | 2.00 | 3.27 | 1.43 | 0.92 | ||||||||||
Operating & Other expenses | 1.00 | 0.89 | 1.41 | 1.13 | 2.65 | 1.56 | 2.49 | 2.32 | 1.10 | 1.21 | ||||||||||
EBITDA | 0.52 | -0.15 | -0.14 | -0.02 | 0.12 | -0.08 | -0.49 | 0.95 | 0.33 | -0.29 | ||||||||||
| Depreciation/Amortization | 0.14 | 0.13 | 0.13 | 0.13 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 | ||||||||||
| PBIT | 0.38 | -0.28 | -0.27 | -0.15 | -0.02 | -0.20 | -0.61 | 0.83 | 0.21 | -0.40 | ||||||||||
| Interest & Other Items | 0.11 | 0.08 | 0.08 | 0.12 | 0.15 | 0.11 | 0.11 | 0.13 | 0.15 | 0.00 | ||||||||||
| PBT | 0.27 | -0.36 | -0.35 | -0.27 | -0.17 | -0.31 | -0.72 | 0.70 | 0.06 | -0.40 | ||||||||||
| Taxes & Other Items | 0.09 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Net Income | 0.18 | -0.36 | -0.35 | -0.27 | -0.23 | -0.31 | -0.72 | 0.70 | 0.06 | -0.40 | ||||||||||
| EPS | 0.17 | -0.37 | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.70 | 0.05 | -0.40 |
NORRIS Company Updates
NORRIS Stock Peers
NORRIS Past Performance & Peer Comparison
NORRIS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Norris Medicines Ltd | -675.60 | -12.05 | — |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
NORRIS Stock Price Comparison
Compare NORRIS with any stock or ETFCompare NORRIS with any stock or ETF
NORRIS
NORRIS Holdings
NORRIS Shareholdings
NORRIS Promoter Holdings Trend
NORRIS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NORRIS Institutional Holdings Trend
NORRIS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NORRIS Shareholding Pattern
NORRIS Shareholding Pattern
NORRIS Shareholding History
NORRIS Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NORRIS stock
smallcases containing NORRIS stock
Looks like this stock is not in any smallcase yet.
NORRIS Events
NORRIS Events
NORRIS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NORRIS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NORRIS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NORRIS has not given any dividends in last 5 years
NORRIS Dividends
NORRIS Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNORRIS Stock News & Opinions
NORRIS Stock News & Opinions
Articles & Videos
Corporate
Corporate
Norris Medicines closes share books September 23-29 for its annual general meetingNorris Medicines Limited informed the BSE Limited that its register of members and share transfer books will remain closed from Wednesday, September 23, 2026, to Tuesday, September 29, 2026, for the purpose of the company's 35th Annual General Meeting scheduled for Tuesday, September 29, 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Norris Medicines’ board approved the Directors Report and scheduled the Annual General MeetingNorris Medicines Limited informed the BSE that its board of directors approved the company’s Directors Report for the financial year ended March 31, 2026, and convened the 35th Annual General Meeting on September 29, 2026, via video conferencing or other audio-visual means, with Mr. Hemant Shetye, or Mr. Kunal Sakpal, appointed as scrutinizer and Purva Sharegistry (India) Pvt. Ltd. authorized to facilitate the e-voting process.
2 weeks agoCapital Market - Live
Corporate
Corporate
Norris Medicines to review quarterly results at August board meeting in AnkleshwarNorris Medicines Limited will hold a board meeting on August 14, 2026, at its registered office in Ankleshwar, Gujarat, to approve the unaudited financial results for the quarter ended June 30, 2026, and to address other business matters, according to a regulatory filing with the BSE Limited. The company has also closed its trading window for securities from July 1, 2026, until 48 hours after the unaudited financial results are announced.
1 month agoCapital Market - Live
Corporate
Corporate
Norris Medicines appoints Iqubal Ismail Patel as CFO, effective July 30, 2026Norris Medicines Limited announced the appointment of Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective July 30, 2026, following a recommendation from the Audit Committee and the Nomination and Remuneration Committee.
1 month agoCapital Market - Live
Corporate
Corporate
Norris Medicines appoints Iqubal Ismail Patel as CFO, effective July 30, 2026Norris Medicines Limited announced the appointment of Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective July 30, 2026, following a recommendation from the Audit Committee and the Nomination and Remuneration Committee.
1 month agoCapital Market - Live
Earnings
Earnings
Norris Medicines reports standalone net profit of Rs 0.05 crore in the March 2026 quarterNet profit of Norris Medicines reported to Rs 0.05 crore in the quarter ended March 2026 as against net loss of Rs 0.23 crore during the previous quarter ended March 2025. Sales declined 48.16% to Rs 1.41 crore in the quarter ended March 2026 as against Rs 2.72 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 0.28 crore in the year ended March 2026 as against net loss of Rs 1.24 crore during the previous year ended March 2025. Sales rose 39.69% to Rs 8.13 crore in the year ended March 2026 as against Rs 5.82 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1.412.72 -48 8.135.82 40 OPM %21.282.57 -8.12-4.47 - PBDT0.17-0.03 LP 0.21-0.64 LP PBT0.05-0.17 LP -0.28-1.18 76 NP0.05-0.23 LP -0.28-1.24 77 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Norris Medicines to discuss resultsNorris Medicines will hold a meeting of the Board of Directors of the Company on 30 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Norris Medicines reports standalone net profit of Rs 0.70 crore in the December 2025 quarterNet profit of Norris Medicines reported to Rs 0.70 crore in the quarter ended December 2025 as against net loss of Rs 0.28 crore during the previous quarter ended December 2024. Sales rose 194.59% to Rs 3.27 crore in the quarter ended December 2025 as against Rs 1.11 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3.271.11 195 OPM %29.05-2.70 - PBDT0.82-0.15 LP PBT0.70-0.28 LP NP0.70-0.28 LP Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Norris Medicines schedules board meetingNorris Medicines will hold a meeting of the Board of Directors of the Company on 14 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Norris Medicines reports standalone net loss of Rs 0.72 crore in the September 2025 quarterNet Loss of Norris Medicines reported to Rs 0.72 crore in the quarter ended September 2025 as against net loss of Rs 0.36 crore during the previous quarter ended September 2024. Sales rose 57.48% to Rs 2.00 crore in the quarter ended September 2025 as against Rs 1.27 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2.001.27 57 OPM %-24.50-11.81 - PBDT-0.60-0.23 -161 PBT-0.72-0.36 -100 NP-0.72-0.36 -100 Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -7.83%, vs industry avg of 11.76%
Over the last 5 years, market share stayed at 0%